Legit.Health and QuantifiCare Partner to Automate Skin Disease Assessment in Clinical Trials
BARCELONA, Spain and BIOT, France (September 18, 2025) — Legit.Health and QuantifiCare signed a partnership agreement to combine their technologies for dermatology clinical trials, creating a platform that pairs 3D imaging hardware with automated disease scoring software.
The collaboration links QuantifiCare's DermaViz and LifeViz imaging systems with Legit.Health's algorithms that detect and measure skin conditions. The companies said the integrated platform cuts patient assessment time by 60 percent and reduces scoring errors compared to manual evaluation.
QuantifiCare, based in the French technology hub Sophia Antipolis, has supplied imaging equipment to dermatology trials for two decades. Legit.Health, headquartered in Barcelona, developed AI software that calculates severity scores for conditions including psoriasis, hidradenitis suppurativa and eczema.
"Dermatology trials have struggled with inconsistent scoring between different raters," said Andy Aguilar, chief executive of Legit.Health. "Automated scoring eliminates that variability. Sponsors get cleaner data, and that can accelerate the path to regulatory approval."
The platform supports more than 15 standardized scoring systems used in dermatology research, including PASI for psoriasis and IHS4 for hidradenitis suppurativa. The software automatically counts and measures lesions from images, tasks that typically require trained specialists to perform manually.
Real-time demonstration of Legit.Health's AI technology. Just by looking at the image, the AI automatically counts acne lesions. The, the investigator may override the result. This automated approach reduces investigator burden and improves data quality in dermatology clinical research.
Jean-Philippe Thirion, chief executive of QuantifiCare, said the partnership addresses demand from pharmaceutical companies seeking to reduce clinical trial costs.
"Our clients want not just high-quality images but intelligent analysis that transforms those images into clinical data," Thirion said. "This partnership delivers both."
Early users of the combined platform reported an 85 percent improvement in consistency between different evaluators and 40 percent faster patient recruitment through automated screening, according to the companies.
The platform is available immediately for new dermatology trials. Deployment options include full-service arrangements with on-site support, software-only implementations, and hybrid models.
Both companies hold regulatory certifications relevant to clinical research. Legit.Health's software carries CE marking as a Class IIb medical device, while QuantifiCare's imaging systems have FDA clearance. Legit.Health has published validation studies for its algorithms in more than 20 peer-reviewed journals.
About Legit.Health
Legit.Health develops AI software that analyzes skin images to measure clinical signs and calculate severity scores across more than 300 conditions. Founded in 2019 in Barcelona, the company serves hospitals, clinics and clinical trial sponsors in Europe, Asia and the Americas. The company holds ISO 13485 certification. For more information, visit legit.health.
About QuantifiCare
QuantifiCare manufactures 2D and 3D imaging systems for clinical research in dermatology, wound care, oncology and medical aesthetics. The company operates in more than 50 countries from headquarters in Sophia Antipolis, France, with offices in the United States and Asia. For more information, visit quantificare.com.
Media Contacts:
Legit.Health press@legit.health
QuantifiCare info@quantificare.com
For complementary information, read the press release published by QuantifiCare.